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Background: Radical cystectomy is the standard treatment for patients with muscle-invasive
urinary bladder cancer; however, is associated with major treatment – related morbidity.
Furthermore, a signiﬁcant proportion of patients are deemed unsuitable for surgery due
to inoperability, advanced age, and/or comorbid conditions. As such, several groups have
explored effectiveness of less radical therapeutic strategies that aimat bladder preservation.
Nonetheless, there is scarcity of reports assessing the applicability of urinary bladder-
sparing outside developed countries.
Aim: Determine the achievable outcomes for patients with muscle-invasive urinary bladder
cancer treated via bladder-sparing techniques in a low income country.
Materials andmethods: Fourteen consecutive patientswith a diagnosis ofmuscle-invasive uri-
nary bladder cancer (clinical stage; T2-3N0M0) were treated via a bladder-sparing approach
at King Hussein Cancer Center (Amman, Jordan) between 2005 and 2009. Records were elec-
tronically retrieved and retrospectively analyzed and included 11 males and 3 females from
41 to 74 years of age (median age, 61). Initial therapy consisted of trans-urethral resection
of bladder tumor (TURBT) followed by induction chemotherapy then irradiation (4500cGy)
with concurrent platinum-based chemotherapy. Urological evaluation directed additional
therapy in a proportion of patients with irradiation (up to 6400 cGy) in patients whoachieved CR.
Results: Eleven patients were evaluable for pathological response at time of re-staging; of
whom 8 (73%) achieved CR and 3 (27%) achieved partial response (PR). In all but one patient;
combined-modality treatment was well tolerated. After a median follow-up of 18.5 months
(range, 3–48 months); 5 of 8 (62.5%) patients with CR were alive.Abbreviations: CR, complete response; PR, partial response; TURBT, transurethral resection of bladder tumor; TCCB, transitional cell
carcinoma of the bladder; cCRT, concurrent chemoradiation.
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Conclusions: Bladder-sparing strategies via concurrent chemoradiation for muscle-invasive
bladder cancer results in an acceptable rate of complete pathological response with ade-
quate short-term outcomes. This approach appears applicable in low-income countries.
© 2011 Greater Poland Cancer Centre, Poland. Published by Elsevier Urban & Partner Sp.
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c. Background
rinary bladder cancer continues to pose a signiﬁcant global
ealth challenge. Transitional cell carcinoma is the most
revalent pathological subtype andapproximately 30%of such
ases are muscle-invasive at the time of diagnosis [100,2].
adical cystectomy is the standard therapy for these patients
ith an expected 5-year survival of 45–60%. However, radical
urgery comes at the cost of long-term morbidity secondary to
rinary diversion techniques.3 As a consequence, numerous
tudies have explored the application of non-surgical strate-
ies in the management of muscle-invasive bladder cancer.4
onetheless, there is scarcity of reports assessing bladder
reservation outside developed countries. We present our
xperience with the use of combined chemoradiation in such
atients in a low-income setting.
. Aim
he aim of this report is to assess the applicability and
etermine the achievable outcomes for patients with muscle-
nvasive urinary bladder cancer treated via bladder-sparing
trategies in a low income country. We intend to report
he indications, complications and therapeutic outcomes of
hemoradiation in these patients. This includes special refer-
nce to the rate of complete pathological response obtained
fter combined-modality therapy. In addition, we will outline
he utilized radiotherapy planning technique. Furthermore,
e intend to shed light on the current status of onco-
ogical healthcare in Jordan focusing on the challenges of
uccessfully implementing bladder-preservation strategies
or muscle-invasive urinary bladder cancer in low-income
ountries.
. Patients and methods
etween March 2005 and June 2008, fourteen patients with
iopsy-proven muscle invasive transitional cell carcinoma
f the bladder (TCCB) were treated via a bladder-sparing
pproach at the King Hussein Cancer Center (Amman, Jordan).
ecords were electronically retrieved and retrospectively ana-
yzed following the acquisition of Institutional Review Board
pproval and included 11 males and 3 females from 41 to
4 years of age (median age 61). Exhaustive chart analysis
as performed in an attempt to extract data pertaining to
athological characters, clinical stage, treatment, disease out-
ome and survival. Patients were evaluated through history,
omplete physical examination and appropriate radiologi-
al (CT chest, abdomen and pelvis) and nuclear imagingz.o.o. All rights reserved.
studies (bone scan). Pathological diagnosis was conﬁrmed
by examining/re-examining biopsy specimens obtained via
trans-urethral biopsy by a staff pathologist at the KHCC. All
tumor specimens demonstrated malignant invasion of mus-
cularis propia. Patients were clinically classiﬁed according to
the 2002 American Joint Committee on Cancer-International
UnionAgainst Cancer classiﬁcation.5 Patientswere excluded if
there was evidence of distant metastases or if chemoradiation
was inappropriate or contraindicated. Cases were discussed
at a joint care conference prior to therapeutic decisions and
delivery of care. Radical cystectomy was inapplicable due to
medical contraindications, patient unsuitability or refusal. Ini-
tial therapy consisted of TURBT (as aggressive as judged to
be safely possible) followed by induction chemotherapy, then
irradiation with concurrent platinum-based agents. Complete
blood counts and biochemical studies were obtained prior to
each dose of chemotherapy. The dose of cisplatin and gem-
citabine was set at 70mg/m2 and 1000mg/m,2 respectively.
Carboplatin was administered instead of cisplatin to patients
with mild renal impairment as bolus infusion once a week, up
to a total dose of 900mg. The dose of cisplatin was reduced
if the serum creatinine concentration rose above 1.5mg/dL.
Severe hematological toxicity was managed via a temporary
discontinuation of chemotherapeutic agents. Radiation ther-
apy was delivered via an Elekta linear accelerator (Elekta
Oncology Systems, Crawley, UK). The bladder and pelvic lym-
phatics were treated via a four-ﬁeld box technique to a total
dose of 4500 cGy given over a period of 5 weeks (180cGy daily
fractions in 5 consecutive days). Planned target volume (PTV)
consisted of the bladder and tumor with 2-cm contoured
margin (Fig. 1). Re-staging cystectomy performed 4 weeks
after the completion of cCRT directed additional therapy with
delivery of irradiation (up to 6400 cGy) in a proportion of
patientswhohadCR (Fig. 2). A complete pathological response
required demonstration of absence of any macroscopically
and microscopically viable tumor in addition to negative urine
cytology. Informed written consent was obtained from all
patients. Follow-up was in the form of a patient visit to a
staff clinician at the KHCC, a patient follow-up phone inter-
view or retrieval from the institutional-tumor registry and
national data archives. The length of the follow-up ranged
from 3 to 48 months, with a median follow-up period of
18.5 months.
4. ResultscCRT was actively recommended as an alternative treat-
ment to radical cystectomy in 8 patients. Three patients
expressed their preference to preserve the native blad-
der, while in 3 patients surgery was contraindicated due
to medical conditions. All patients received the scheduled
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Table 1 – Patient characteristics and outcome.
No Age/sex Tumor/stageInduction
chemother-
apy
Indication
for bladder
preserva-
tion
Concurrent
chemother-
apy
Pelvic RT/Gy Bladder
RT/Gy
Initial
evaluation
Local
recurrence
Distant
recurrence
Status F/U in months
1 53/M T3bN0 Gemcitabine
Cisplatin
Recommended
by physician
Cisplatin 45 – CR No No Alive
NED
27
2 63/M T2N0 Gemcitabine
Carboplatin
Patient
preference
Cisplatin 45 – CR No No Alive
NED
47
3 74/M T2aN0 Gemcitabine
Carboplatin
Patient
preference
Cisplatin 45 19 CR No No Alive
NED
11
4 71/M T2N0 Gemcitabine
Cisplatin
Recommended
by physician
Carboplatin 45 19 CR No No Alive
NED
6
5 61/M T2N0 Gemcitabine
Cisplatin
Cardiac
disease
Cisplatin 45 19 CR No No Alive
NED
21
6 61/M T2aN0 Gemcitabine
Carboplatin
Recommended
by physician
Carboplatin 45 – CR No No Dead
NED
14
7 65/M T2N0 Gemcitabine
Cisplatin
Recommended
by physician
Cisplatin 45 – CR No Lung
Bone
Dead
DTD
48
8 61/F T2N0 Gemcitabine
Cisplatin
Morbid
obesity
Cisplatin 45 16 CR No Pelvic
LNs
Dead
DTD
47
9 60/M T3N0 Gemcitabine
Cisplatin
Recommended
by physician
Cisplatin 45 – Not evaluated – – Alive
UDS
3
10 56/F T3bN0 Gemcitabine
Cisplatin
Recommended
by physician
Cisplatin 45 – PR Residual
disease
Pelvic
LNs
Dead
DTD
16
11 63/M T2N0 Gemcitabine
Cisplatin*
Patient
preference
Cisplatin 45 – PR Residual
disease
Bone Dead
DTD
4
12 49/M T2N0 Gemcitabine
Cisplatin
Recommended
by physician
Carboplatin 45 – PR Residual
disease
PALNs
Bone
Alive
WD
24
13 41/F T2N0 Gemcitabine
Carboplatin
Recommended
by physician
Cisplatin 45 – Not evaluated – Liver
Lung
Bone
Dead
DTD
5
14 59/M T2aN0 Gemcitabine
Cisplatin
COPD Cisplatin 45 – Not evaluated – Lung Dead
DTD
14
PALN, para-aortic lymph node; NED, no evidence of disease; DTD, due to disease; UDS, unknown disease status; WD, with disease; COPD, chronic obstructive pulmonary disease.
∗ Patient could not tolerate regimen (developed meningitis).
reports of practical oncology and radiotherapy 1 6 ( 2 0 1 1 ) 178–183 181
atic
i
a
t
e
t
t
e
a
s
i
o
t
p
l
u
w
o
w
5
U
hFig. 1 – Bladder and pelvic lymph
nduction/concurrent chemoradiation doses as planned. In
ll but one patient, combined-modality treatment was well
olerated (one patient developed meningitis). Nine patients
xhibited WHO grade I and/or II hematological, gastroin-
estinal and urinary toxicity. Evaluation of local response via
rans-urethral cystoscopic-guided biopsy was performed in
leven patients, of whom 8 (73%) achieved CR and 3 (27%)
chieved PR. Two of the three patients who did not have cysto-
copic evaluation developed distant metastases shortly after
nitial treatment while the third patient lost follow-up. Four
ut of the 8 patients who achieved CR were treated with addi-
ional bladder irradiation up to 6400 cGy. The remaining 4
atients lost follow-up. None of the patients demonstrated
ate toxicity at the timeof the follow-up.After amedian follow-
p of 18.5 months (range 3–48 months); 5 of 8 (62.5%) patients
ith CR were alive. Local recurrence was not observed in any
f the patients who achieved CR (Table 1). None of the patients
ho achieved PR went on to undergo salvage cystectomy.. Discussion
rinary bladder cancer continues to pose a signiﬁcant global
ealth challenge. In the Western world, bladder cancer is theirradiation isodose distributions.
fourth most common malignancy in men and the eighth most
common in women.6 In Jordan, cancers of the urinary bladder
accounted for 69.2% of all urinary tract cancers in 2008 rank-
ing the third and the twenty seventh most prevalent cancer
among males and females, respectively, with a male to female
ratio of 6.3:1. Worldwide, the most prevalent pathological sub-
type is transitional cell carcinoma accounting for up to 90%
of cases [100,2]. Similarly, TCC constitutes over 95% of bladder
cancers in Jordan.7 Muscle invasion – estimated tooccur in 30%
of cases – is a major prognostic factor since it requires more
aggressive therapy.1,8 Radical cystectomy is the standard treat-
ment for such patients resulting in a 5-year overall survival of
about 45–60%.9,10 This holds true in the US; where radical cys-
tectomy remains the preferred primary treatment modality
for organ-conﬁned (T2–4N0M0) disease.3 However, since blad-
der cancer is generally diagnosed after the age of 65, and rarely
before 40 years of age, a signiﬁcant number of patients are
deemed unsuitable for surgery due to inoperability, advanced
age, or comorbid conditions.11 Radical cystectomy, in addition,
markedly affects the quality of life secondary to urinary diver-
sion techniques and the associated rehabilitation necessary
subsequent to neo-bladder construction.3 The non-continent
state following urinary diversion has signiﬁcant physical
and psychological implications.12 Furthermore, complications
182 reports of practical oncology and radiotherapy 1 6 ( 2 0 1 1 ) 178–183
ownFig. 2 – Bladder and tumor cone-d
following radical cystectomy include hemorrhage, infection,
urinary leaks, pelvic lymphoceles, intestinal obstruction, and
peritonitis.13 This previous statement was reiterated by Haut-
mann and collegues who reported their experience with 1000
radical cystectomies and subsequent neobladder formation.14
Therefore, several groups have explored less radical ther-
apeutic strategies that aim at bladder preservation.4 Ideal
candidates are patients with solitary T2 or T3 tumors,
with no evidence of ureteral obstruction, a visibly complete
transurethral tumor resection, with no evidence of pelvic
lymph node metastases and adequate renal function2,15,16 ork
between the urologist,medical and radiation oncologist is cru-
cial for the successful completion of such organ-preserving
strategies.2
The concept of combined administration of chemoradia-
tion is designed to maximize the interaction between ionizing
radiation and chemotherapeutic agents.3 At the radiobiolog-
ical level, chemotherapy appears to act synergistically with
radiotherapy by targeting cells in the radio-resistant phases
of the growth cycle, leaving a population of synchronized,
more radiosensitive cells.3 The basis behind such interactions
includes spatial co-operation, prevention of emergence of
resistant clones, hypoxic cell sensitization, hypoxic cell killing,
inhibition of potentially lethal and sub-lethal radiation-irradiation isodose distributions.
induced damage repair and inhibition of cellular repopulation
during fractionated radiotherapy.3 Cisplatin has been exten-
sively investigated for its interaction with ionizing radiation.3
Speciﬁcally, cisplatin exerts its cytotoxic effects by chelating
guanine residues, yielding monofunctional adducts and intra-
strand or inter-strand crosslinks.3 The ﬁrst phase II study
reporting the concurrent use of cisplatin with pelvic radio-
therapy in bladder cancer was published in 1982.17 More
recently, a number of phase III clinical trials reporting patients
randomized to cisplatin plus radiotherapy versus radiother-
apy alone demonstrated a signiﬁcant improvement in pelvic
recurrence-free survivalwith combined treatment, in addition
to improved bladder preservation, althoughno overall survival
difference was observed.18 The proposed standard radiother-
apy regimen for invasive bladder cancer is irradiation of the
whole bladder and tumor with a 2-to 3-cm margin to a dose
of 60–66Gy.19
Nonetheless, there are no randomized phase III clinical
trials directly comparing radical cystectomy and chemoradio-
therapy in muscle-invasive bladder carcinoma.13 Comparing
results from the non-randomized trials of chemoradiation
with contemporary cystectomy series is fraught with dif-
ﬁculty secondary to the considerable discrepancy between
clinical staging and pathologic staging, which broach forth
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s important confounding factors in contrasting results of
urgery with those of bladder preservation.3,20 However, a
onsiderable number of studies have shown that in terms
f disease-speciﬁc survival radical radiotherapy results are
quivalent to those for radical surgery at 5 years and 8 years.13
ecently, a retrospective cohort from the United Kingdom
eported no statistical difference in all-cause survival between
urgery and radiotherapy at a minimum follow-up period of
0 years.20 Thus, the use of bladder-preservation therapy for
uscle-invasive TCC of the bladder is a valid alternative in
elected cases with long-term efﬁcacy comparable to radical
ystectomy, with the added advantage of preserving excel-
ent bladder function in the majority of long-term survivors.21
rospective studies have reported encouraging quality of life
valuations for such patients.22
In Jordan, oncological healthcare is delivered via national,
niversity and private hospitals. National hospitals are
unded, managed and operated by the Ministry of Health
nd provide near-global low-cost primary care coverage. Uni-
ersity hospitals, on the other hand, deliver specialized
ertiary care. Private hospitals deliver fee-for-service care.
he King Hussein Cancer Center is the sole comprehen-
ive cancer center in the country. Unfortunately, several gaps
inder the provision of comprehensive quality care for can-
er patients outside our institution, including inappropriate
linical practices, insufﬁcient implementation of evidence-
ased medicine and unbalanced physical distribution of care
roviders.23 In this small series, we demonstrated the appli-
ability of bladder-preserving combined-modality therapy in
low income-country. Unfortunately, there are no published
eports assessing outcomes of radical cystectomy for bladder
ancer in Jordan and, therefore, we are unable to compare our
esults with those of a surgery series. Nonetheless, and while
cknowledging the limitations of our study including the ret-
ospective nature, small sample size and the short follow-up
eriod, we report a rate of complete pathological response
n lieu with previously published reports. However, lifelong
ladder surveillance is paramount, since only prompt salvage
herapy can prevent a focus of a new or recurrent bladder
ancer from disseminating.4
onﬂict of interest
one.
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